TY  - JOUR

T1  - Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

JO  - JOURNAL OF CLINICAL ONCOLOGY

UR  - https://eprints.whiterose.ac.uk/id/eprint/101665

UR  - http://dx.doi.org/10.1200/JCO.2015.64.8808

PY  - 2016/05/10

AU  - Powles T

AU  - Lackner MR

AU  - Oudard S

AU  - Escudier B

AU  - Ralph C

AU  - Brown JE

AU  - Hawkins RE

AU  - Castellano D

AU  - Rini BI

AU  - Staehler MD

AU  - Ravaud A et al

ED  - 

DO  - DOI: 10.1200/JCO.2015.64.8808

PB  - American Society of Clinical Oncology

VL  - 34

IS  - 14

SP  - 1660

EP  - U204

Y2  - 2025/11/03

ER  -